Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Gastroenteritis. According to GlobalData, Phase III drugs for Gastroenteritis does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Dupilumab LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dupilumab overview
Dupilumab (REGN-668, SAR231893, Dupixent, Dubrantis) is a monoclonal antibody produced by recombinant DNA technology. It is formulated as an injectable solution for subcutaneous route of administration. Dupilumab is indicated for the treatment of asthma, atopic dermatitis (atopic eczema), nasal polyps (nasal polyposis). Dupixent is indicated for the treatment of adults and pediatrics patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
It is under development for the treatment of prurigo nodularis, grass pollen allergy, gastroenteritis, chronic spontaneous urticaria or hives, dermatitis (eczema), chronic obstructive pulmonary disease (COPD), chronic bronchitis, alopecia areata, bullous pemphigoid, prurigo, systemic sclerosis (scleroderma), pruritus, allergic bronchopulmonary aspergillosis, atopic keratoconjunctivitis, asthma, immunoglobulin g4-related disease (igg4-rd), atopic dermatitis (atopic eczema), eosinophilic gastritis with or without eosinophilic duodenitis, rhinosinusitis, metastatic non-small cell lung cancer and ulcerative colitis. It is based on VelocImmune technology.
It was under development for peanut allergy, prostate cancer and rhinosinusitis.
Regeneron Pharmaceuticals overview
Regeneron Pharmaceuticals (Regeneron) discovers, develops, manufactures, and markets medicines for the treatment of serious medical conditions. Its products are focused on helping patients suffering from cancer, allergic and inflammatory diseases, eye diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, hematologic conditions, pain, and rare diseases. Regeneron develops products using its Trap and VelociSuite technology platforms, which include VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, and other related technologies. The company operates manufacturing facilities in Rensselaer, New York, and Limerick. It also collaborates with strategic partners to develop, manufacture and commercialize its products. The company sells its products to specialty pharmacies and distributors. It operates in the US, the Netherlands, Bermuda, Ireland, Spain, India, Japan and the UK. Regeneron is headquartered in Tarrytown, New York, the US.
For a complete picture of Dupilumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
